SAN DIEGO and MENLO PARK, Calif., July 18, 2017 (GLOBE NEWSWIRE) -- Novogene, a leading global provider of genomic services and solutions, and Pacific Biosciences of California, Inc. (NASDAQ:PACB), the leader in long-read sequencing, have agreed to jointly develop and promote novel applications based on the PacBio® Sequel® System. New applications developed under this agreement are expected to focus on basic and translational research in the field of precision medicine, including methods for sample processing, workflow automation, algorithm development, and database construction.
Sequel Systems are based on Single Molecule, Real-Time (SMRT®) technology, which has the advantage of uniform coverage across all genome regions, including palindromes and low-diversity regions of the genome. Genome sequencing with PacBio Systems helps provide more complete and accurate views of all types of genomic variation, revealing SNPs/SNVs, structural variants, mobile elements, haplotypes, epigenetics, and variants in low-complexity regions. Furthermore, the isoform sequencing (Iso-Seq®) method with the Sequel System generates full-length cDNA sequences, which can be used to profile the full complexity of the human transcriptome and discover novel genes, isoforms, and gene fusion events.
With the ability to run up to 10 PacBio Sequel Systems, Novogene operates in a facility that has the largest capacity for SMRT Sequencing in a single location. As a leading genomic service provider with a comprehensive portfolio of service products, Novogene has extensive expertise in developing and marketing high-quality end-to-end service solutions, from sample preparation to data analysis and interpretation, for a variety of applications in diverse research and clinical fields.
About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene pursues scientific excellence, strong commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly developing world of genomics. With 1,800 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, Novogene has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses, quality, performance or advantages of, or benefits of using, products or technologies, future development or promotional efforts, the expected benefits of the company’s collaboration with Novogene, the suitability of the company’s products for particular markets or applications and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.